AAH Pharmaceuticals
AAH Pharmaceuticals is the UK's largest pharmaceutical wholesaler, supplying approximately 14,000 pharmacies nationwide. It is included here solely because it distributes Teva pharmaceutical products across the UK market, generating revenue for Israel's largest company.
Take Action
Apply pressure where it matters. Use these tools and personalise your message with evidence from this page.
- Contact Corporate LeadershipPre-filled letter templates for pharmacy and procurement professionals
- Report New IntelligenceSubmit evidence of contracts, partnerships, or distribution agreements
- Share This ProfileShare on LinkedIn to reach pharmacy and healthcare professionals
- Strategic AnalysisIn-depth analysis and engagement strategy
Before taking action, review our Code of Conduct for professional standards and ethical guidelines.
Help Us Hold AAH Pharmaceuticals Accountable
Your skills and knowledge can strengthen this campaign. Join our volunteer research team or share insider information securely.
Leverage Your Expertise
Do you work in this sector? We need professionals who understand procurement cycles, regulatory compliance, and corporate governance. Don't just boycott - lead!
Decision-Maker Directory
Key individuals with influence over corporate partnerships and procurement decisions. Direct your correspondence to the most relevant role.
Material Risk Framing
Frame your message around business risks. These talking points resonate with corporate stakeholders and institutional investors.
As the UK's largest pharmaceutical wholesaler, AAH's distribution of products from Israel's largest company, which the ICJ found faces a 'plausible' genocide case (January 2024), creates reputational exposure with NHS trusts and pharmacy chains increasingly scrutinising supply chain ethics
AAH's role as a distribution intermediary means it could face pressure from pharmacies requesting non-Teva alternatives; however, all major UK wholesalers currently distribute Teva products, limiting the impact of individual wholesaler pressure
Owned by Aurelius Group since 2022; private equity ownership may create sensitivity to sustained reputational pressure that could affect future divestiture or refinancing prospects
UK procurement law and emerging due diligence legislation may create obligations for wholesale distributors sourcing from companies contributing significant revenue to states facing international legal proceedings
Strategic Analysis
In-depth assessment of the company's position, vulnerabilities, and recommended approaches for effective engagement.
Lower severity, high vulnerability — momentum builders that fold quickly
Learn about our methodology — companies are categorised based on severity (harm potential) vs strategic vulnerability (campaign leverage).
Why do these scores change?
Unlike static boycott lists, our targeting model is dynamic. This company's position on the matrix is re-evaluated continually as we verify new contracts, divestments, or policy changes. Your reporting directly impacts this score.
AAH Pharmaceuticals is included in this directory solely because of its role as the UK's largest distributor of Teva pharmaceutical products. We are not making a broader judgement on AAH's business practices. The focus is on the supply chain relationship that generates revenue for Israel's largest company.
Why AAH Matters
Teva supplies approximately one in six of all prescription medicines dispensed in the UK. As the UK's largest wholesale distributor, AAH is a critical link in Teva's access to approximately 14,000 UK pharmacies. While AAH does not manufacture Teva products, its distribution network is essential to Teva's UK market presence and revenue generation.
The Wholesaler Challenge
All major UK pharmaceutical wholesalers currently distribute Teva products. This means simply switching wholesaler does not reduce Teva's market access. The effective action is for pharmacies to request non-Teva generic alternatives from their existing wholesaler, including AAH. The generic pharmaceutical market is highly competitive, and equivalent alternatives from non-Israeli manufacturers exist for most Teva products.
Key Leverage Points
- Pharmacy Demand: Pharmacies can specify non-Teva generics when ordering from AAH. Wholesale purchasing is demand-driven — if pharmacies stop ordering Teva products, AAH's procurement from Teva decreases
- NHS Procurement: Hospital pharmacy leads and ICB procurement officials can include ethical sourcing criteria in tender specifications, influencing wholesale distribution patterns
- Private Equity Sensitivity: Aurelius Group's ownership creates sensitivity to reputational risk that could affect future divestiture valuations
Engagement Strategy
In addition to pressuring AAH directly, an effective approach targets the demand side: engage pharmacists and pharmacy owners to request non-Teva alternatives when placing wholesale orders. For comprehensive medication alternatives, see our Teva alternatives guide, which covers substitutions across all major therapeutic categories.
Evidence & Sources
Verified sources including NGO reports, regulatory filings, and primary documents. Use these to substantiate your correspondence.
Confirms position as the UK's largest pharmaceutical wholesaler, supplying approximately 14,000 pharmacies from 20 distribution locations nationwide
Open sourceTeva confirms it supplies approximately one in six of all prescription medicines dispensed in the UK, distributed through the wholesale network including AAH
Open sourceGerman private equity firm Aurelius acquired AAH Pharmaceuticals as part of the McKesson UK carve-out for approximately 900 million pounds, forming Hallo Healthcare Group
Open sourceResearch shows Teva contributed approximately 10% of Israel's total industrial GDP (2003-2012), establishing why distribution of Teva products is strategically significant
Open sourceUpdates & Milestones
- Continued Growth
AAH continues to operate as the UK's largest pharmaceutical wholesaler under Aurelius Group ownership
- Aurelius Acquisition
German private equity firm Aurelius acquires AAH from McKesson for approximately 900 million pounds, forming Hallo Healthcare Group
- McKesson Acquisition
US healthcare giant McKesson Corporation acquires AAH as part of its European expansion
- AAH Founded
Established as a UK pharmaceutical wholesale distributor